Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.39 |
| ▸ | CAD | P27708 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 7/20 | 0.36 |
| ▸ | METAP1 | P53582 | 4/20 | 0.36 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.35 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25760765 | 0.87 | L3MBTL1 (0.42) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL18478761 | 0.86 | L3MBTL1 (0.46) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL20468542 | 0.85 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL24328877 | 0.85 | L3MBTL1 (0.44) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL21473367 | 0.84 | L3MBTL1 (0.39) | L3MBTL1KMT2APOLBNOD1 | |
| SCHEMBL24327858 | 0.84 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL18451341 | 0.83 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL20465422 | 0.83 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL26946464 | 0.83 | L3MBTL1 (0.43) | L3MBTL1KMT2APOLBNOD1CAD | |
| SCHEMBL20468546 | 0.82 | NOD1 (0.51) | NOD1DPP8DPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | Ústav organické chemie a biochemie AV CR, v.v.i. (CZ) | 2021-07-08 | — | — | US | disclosed |
| US-10954257-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2021-03-23 | — | — | US | disclosed |
| US-10738066-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2020-08-11 | — | — | US | disclosed |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2019-10-17 | — | — | US | disclosed |
| US-10336778-B2 | Prodrugs of glutamine analogs | THE JOHNS HOPKINS UNIVERSITY (US) | 2019-07-02 | — | — | US | disclosed |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), AS COLLATERAL AGENT | 2018-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210206787-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | L3MBTL1 627/4885KMT2A 1913/4885POLB 2242/4885 |
| US-10738066-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
| US-20190315783-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
| US-10336778-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
| US-10954257-B2 | Prodrugs of glutamine analogs | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
| US-20180222930-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
| US-20190315784-A1 | PRODRUGS OF GLUTAMINE ANALOGS | GLUL, GLS, GLS2 | L3MBTL1 406/4885KMT2A 2112/4885POLB 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.